Copyright
©The Author(s) 2019.
World J Gastroenterol. Jun 14, 2019; 25(22): 2809-2818
Published online Jun 14, 2019. doi: 10.3748/wjg.v25.i22.2809
Published online Jun 14, 2019. doi: 10.3748/wjg.v25.i22.2809
Author (year) | Remission | Treatment failure | Relapse |
Schramm et al[6], 2001 | IAIHG revised criteria (1999) | - | IAIHG revised criteria (1999) |
Granito et al[21], 2005 | IAIHG revised criteria (1999) | - | IAIHG revised criteria (1999) |
Al-Chalabi et al[23], 2006 | IAIHG revised criteria (1999) | IAIHG original criteria (1993) | IAIHG revised criteria (1999) |
PR: IAIHG original criteria (1993) | |||
Czaja et al[9], 2006 | Symptoms: Absent | Worsening of clinical, laboratory and/or histological alterations despite compliance to therapy | Symptom recurrence and increased serum AST level (> three-fold the ULN) after drug withdrawal |
AST level: Normal or near normal (< two-fold the UNL) | |||
Histology: Minimal/no inflammation | |||
SR: | |||
Symptoms: Absent | |||
Serum AST levels: Normal or below the relapse threshold | |||
after drug withdrawal | |||
Zhang et al[22], 2012 | Symptoms: Absent | Worsening of clinical, laboratory and/or histological alterations despite compliance to therapy | Symptom recurrence and increased serum AST level (> three-fold the ULN) after drug withdrawal |
AST levels: Normal or near normal (< two-fold the UNL) | |||
Histology: Minimal or no inflammation. | |||
SR: | |||
Symptoms: Absent | |||
AST levels: Normal or below the relapse threshold after drug withdrawal | |||
Zachou et al[20], 2016 | CR: | Persistently elevated AST and ALT (> three-fold the UNL) and/or increased IgG despite intensive immunosuppression and compliance to therapy | Rise in AST and ALT levels (> three-fold the UNL) and/or increased IgG (> 2000 mg/dL) during therapy with or without symptom recurrence after initial CR |
Symptoms: Improved | |||
AST, ALT, IgG levels: normal | |||
Histology: Minimal/no inflammation | |||
PR: | |||
ALT or AST levels: Decreased (< two-fold ULN) without achieving complete normalization and inability to withdraw or taper prednisolone | |||
Morii et al[24], 2017 | Normal serum ALT and IgG levels | - | Re-exacerbation not explicitly defined |
- Citation: Durazzo M, Lupi G, Scandella M, Ferro A, Gruden G. Autoimmune hepatitis treatment in the elderly: A systematic review. World J Gastroenterol 2019; 25(22): 2809-2818
- URL: https://www.wjgnet.com/1007-9327/full/v25/i22/2809.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i22.2809